tbuckley/cabot-search huggingface dataset:
Multiplex Quantum Dot ISH Measurement of Gene Expression in Tissue Microarrays Identifies HOXA9 and DNMT3A as Markers of Poor Response to Chemotherapy in Patients with Acute Myeloid Leukaemia
Authors: Eleni Tholouli, Sara A MacDermott, Judith A Hoyland, Caroline Glennie, Ric Swindell, John Liu-Yin, Richard J Byers
Journal: Blood (2008)
CD34+ Cell Selection Is Required to Accurately Measure HOXA9 Levels by Quantitative RT-PCR in Patients with Myelodysplastic Syndrome.
Authors: Jason N. Berman, Stefan Heinrichs, Taylor M. Ortiz, Steven M. Kornblau, Donna S. Neuberg, Elihu H. Estey, A. Thomas Look
Journal: Blood (2004)
Lysophosphatidic acid signaling through its receptor initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor
Authors: Norihiko Sakai, Jerold Chun, Jeremy S. Duffield, David Lagares, Takashi Wada, Andrew D. Luster, Andrew M. Tager
Journal: Kidney International (2016)
Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling.
Authors: Ravi K. Amaravadi, Naznin Haq, Stephan W. Morris, D. Gary Gilliland, David W. Sternberg
Journal: Blood (2004)
Is Prevention of Myeloid Leukemia Possible?.
Authors: Katarina Reinhardt, Marjolein Blink, Annette Sander, Christine von Neuhoff, Katarina Boehmer, Alexandra Kolenova, Jan Stary, Denisa Mendelova, Jan-Henning Klusmann, Dominik Schneider, Valerie de Haas, Claudia Rossig, Marry M. van den Heuvel, Ursula Creutzig, C. Michel Zwaan, Dirk Reinhardt
Journal: Blood (2009)
Transduction of Macaque Hematopoietic Repopulating Cells with Lenti and Foamy Retroviral Vectors with MGMT Selection Cassettes To Evaluate AIDS Gene Therapy Strategies.
Authors: Grant D. Trobridge, Brian C. Beard, David Dickerson, Christina Gooch, Philip Olsen, James Fletcher, Ming-Jie Li, Shiu-Lok Hu, John J. Rossi, Hans-Peter Kiem
Journal: Blood (2006)
A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma
Authors: Pamela S. Becker, Ted A. Gooley, Kathy Lilleby, Damian J. Green, Nicholas Burwick, Christine Wallace, Theodore Kim, Kiarash Kojouri, Erin Nelli, William I. Bensinger
Journal: Blood (2012)
O-012 Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis
Authors: J. Henriques, D. Vernerey, A. de Gramont, B. Chibaudel, E. Van Cutsem, A. Falcone, R.M. Goldberg, Q. Shi, F. Bonnetain, E. Shmueli
Journal: Annals of Oncology (2016)
NK/T Cell Versus Peripheral T Cell Lymphoma: Significant Differences in Clinical Characteristics and Survival.
Authors: Soon-Thye Lim, Fei Gao, Lay-Cheng Lim, Richard Quek, Daryl Lim, Swee-Peng Yap, Susan Loong, Ivy Sng, Miriam Tao
Journal: Blood (2006)
Percutaneous Femoroplasty, Ileoplasty and Sacroplasty in the Treatment of Bone Lytic Lesions in Advanced Multiple Myeloma Patients
Authors: Daniele Derudas, Claudio Pusceddu, Roberta Murru, Affra Carubelli, Gabriele Podda, Emanuele Angelucci
Journal: Blood (2008)
Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization.
Authors: Christina Kalpadakis, Marina P. Siakantaris, Marie-Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Tatiana Tzenou, Maria N. Dimopoulou, Evangelia M. Dimitriadou, Styliani I. Kokoris, Maria K. Angelopoulou, Fotios Mitropoulos, Penelope Korkolopoulou, Gerassimos A. Pangalis
Journal: Blood (2005)
Infographic. General guidance for the prevention of illness in athletes
Authors: Martin Schwellnus, Torbjørn Soligard, Juan Manuel Alonso, Roald Bahr, Ben Clarsen, H Paul Dijkstra, Tim J Gabbett, Michael Gleeson, Martin Hägglund, Mark R Hutchinson, Christa Janse Van Rensburg, Romain Meeusen, John W Orchard, Babette M Pluim, Martin Raftery, Richard Budgett, Lars Engebretsen
Journal: British Journal of Sports Medicine (2016)
Pregnancy out Come In the Perspective of Chronic Myeloid Leukemia Patient on Imatinib Therapy: An Experience From India.
Authors: Soma Mukhopadhyay, Ashis Mukhopadhyay, Swati Dasgupta, Subhasish Dey, Deboshree Majumdar, Sanjoy Sarkar, Firoj Gharami, Sukanta Konar, Ujjal Ray
Journal: Blood (2010)
Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes
Authors: Ambarish Pandey, Harsh Golwala, Haolin Xu, Adam D. DeVore, Roland Matsouaka, Michael Pencina, Dharam J. Kumbhani, Adrian F. Hernandez, Deepak L. Bhatt, Paul A. Heidenreich, Clyde W. Yancy, James A. de Lemos, Gregg C. Fonarow
Journal: JACC Heart Failure (2016)
The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)
Authors: Christopher Fegan, Joanne Bagshawe, Gilles Salles, Lionel Karlin, Simon Rule, Nimish Shah, Franck Morschhauser, Louis Terriou, Martin JS Dyer, Harriet Walter, Claire Hutchinson, Guillaume Cartron, John Sharpe, Kevin Duffy, Akhisa Nishimura, Shin-ichiro Abe, Hideyuki Honda, Tomoko Yasuhiro, Toshio Yoshizawa, Joseph Birkett, Nigel Courtenay-Luck
Journal: Blood (2014)
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?
Authors: Marlieke E. A. de Kraker, Andrew J. Stewardson, Stephan Harbarth
Journal: PLoS Medicine (2016)

Points• A recent high profile report estimates that, by 2050, 10 million people will die every year due to antimicrobial resistance (AMR) unless a global response to the problem of AMR is mounted.• There is undoubtedly a large clinical and public health burden associated with AMR, but it is challenging to quantify the associated excess morbidity and mortality.• When estimates of the burden of AMR are provided, they should be accompanied by clear acknowledgment of the associated uncertainties regarding the incidence of infections, the prevalence of resistance, and the attributable mortality.• Predictions always require assumptions, but modeling future scenarios using unreliable contemporary estimates is of questionable utility.• Current global estimates of the burden of AMR are not very informative; we need detailed, reliable data to be able to improve AMR control measures, preferably based on comprehensive, population-based surveillance data from low-, middle-, and highincome countries.In 2014, Lord Jim O'Neill and his team published a review commissioned by the United Kingdom government entitled, "Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations" (the AMR Review) [1].The review estimated that antimicrobial resistance (AMR) could cause 10 million deaths a year by 2050.This estimate has become a familiar refrain; it has been quoted repeatedly by lay media, experts, and public health agencies.Frequently, only this specific, frightening conclusion is reproduced from the report, unaccompanied by caveats or confidence intervals.We acknowledge that there is a large clinical and public health burden associated with AMR, that this burden is likely to increase over time, and that urgent action is required [2,3].However, we contend that unreliable global estimates like those provided in the AMR Review [1] potentially undermine, rather than support, the fight against a post-antibiotic era.In this essay, we will scrutinize the estimations of the burden of AMR provided by the AMR Review [1] and highlight the uncertainties behind these estimates.These uncertainties need to be addressed in order to produce more reliable, detailed, and actionable results.
Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma
Authors: Peter A. Forsberg, Tomer M Mark, Sujitha Yadlapati, Adriana C Rossi, Roger N Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Ruben Niesvizky, Scott Ely
Journal: Blood (2015)
Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota
Authors: A. Sloan Devlin, Angela Marcobal, Dylan Dodd, Stephen Nayfach, Natalie Plummer, Tim Meyer, Katherine S. Pollard, Justin L. Sonnenburg, Michael A. Fischbach
Journal: Cell Host & Microbe (2016)
Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Study in Japan
Authors: Kazuyoshi Ishii, Shosaku Nomura, Shinya Fujita, Atushi Satake, Tomoki Ito, Yuta Katayama, Taiichi Kyo, Shuichi Ota, Masanori Seki, Shigeru Chiba, Yoshinobu Maeda, Mitsune Tanimoto, Takayuki Ikezoe, Hideo Yagi, Kunio Hayashi, Yoji Ishida, Naohito Fujishima, Kenichi Sawada, Masaya Okada, Hiroyasu Ogawa
Journal: Blood (2015)
Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).
Authors: François Guilhot, Claude Preudhomme, Joelle Guilhot, Francois-Xavier Mahon, Franck Emmanuel Nicolini, Francoise Rigual-Huguet, Laurence Legros, Agnès Guerci, Delphine Rea, Valerie Coiteux, Frederic Maloisel, Martine Gardembas, Claude-Eric Bulabois, Marc G Berger
Journal: Blood (2009)
Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.
Authors: Stefan Heinrichs, Rima V. Kulkarni, Carlos E. Bueso-Ramos, Mignon Loh, Ross Levine, Cheng Li, Donna S. Neuberg, Steve M. Kornblau, Jean-Pierre Issa, D. Gary Gilliland, Elihu H. Estey, A. Thomas Look
Journal: Blood (2007)
Increased Adhesive Properties and Reactive Oxygen Species of Red Cells, Platelets and Leukocytes and Neutrophil Chemotaxis in IVS-1-6 (T → C) Homozygous β-Thalassemia Intermedia.
Authors: Carla Fernanda Franco-Penteado, Marcos André Cavalcanti Bezerra, Mariana R. B. Mello, Sheley Gambero, Dulcinéia M Albuquerque, Carolina Lanaro, Sara T.O. Saad, Aderson S. Araújo, Fernando F. Costa
Journal: Blood (2008)
Identification and Characterization of Novel SET Domain-Containing Histone Lysine Methyltransferase and Implications of Histone Methylation in Acute Leukemia.
Authors: Hoon Kook, Nakwon Choe, Hae-Jin Kee, Sung-Mi Kim, Ji-Young Kim, Dong-Kyun Han, Hee-Jo Baek, Kun-Soo Lee, Tai-Ju Hwang, Sang-Beom Seo, Hyun Kook
Journal: Blood (2006)
A Risk-Adapted, Response-Based Therapeutic Regimen Using a Modified Stanford V Approach for the Treatment of Children with High Risk Hodgkin Lymphoma, AHOPCA LH 2004, a therapeutic regimen from the Central America and Dominican Republic Association of Pediatric Oncology.
Authors: E. Mauricio Castellanos, Monika Metzger, L. Fulgencio Baez, Yessica Gamboa, Armando Pena Hernandez, Soad Alabi, Sandra Luna-Fineman, Rosa Nieves, Pedro de Alarcon
Journal: Blood (2009)
Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewisy Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,
Authors: Paul Neeson, Amit S Khot, Stefan Peinert, Tsin Y Tai, Karen Chen, Kellie Tainton, Dominic Wall, Dirk Hoenemann, Michael H Kershaw, Jennifer Westwood, Joe Trapani, Mark J Smyth, Phillip Darcy, Andrew Scott, Lucy Kravets, Jill Davison, Michael J. Dickinson, David Ritchie, Miles Prince
Journal: Blood (2011)
Dihydroflavonol BB-1, an Extract of Natural Plant Blumea Balsamifera, Abrogates TRAIL Resistance in Adult T-Cell Leukemia/Lymphoma.
Authors: Hiroo Hasegawa, Yasuaki Yamada, Masahiko Hayashi, Masami Ishibashi, Kanki Komiyama, Ken Murata, Masato Masuda, Nobuyuki Takasu, Masao Tomonaga, Shimeru Kamihira
Journal: Blood (2004)
Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells.
Authors: Warren Fiskus, Yongchao Wang, Anand Jillella, Celalettin Ustun, Pace Johnston, Rajeshree Joshi, Rekha Rao, Peter Ataja, Victor Marquez, Kapil N. Bhalla
Journal: Blood (2008)
Evaluation of Prognostic Factors for Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance
Authors: Federico Sackmann, Claudia Corrado, Isolda Fernandez, Miguel A Pavlovsky, Pablo Mountford, Astrid Pavlovsky, Miguel Pavlovsky, Mariel Alejandre, Marco Pizzolato, Santiago Pavlovsky
Journal: Blood (2008)
The C1542G and G505A Polymorphisms of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Thrombotic Microangiopathies.
Authors: Christoph Sucker, Firuseh Farokhzad, Fieras Dahhan, Michael Schmitz, Gerd R. Hetzel, Bernd Grabensee, Rainer B. Zotz, Rudiger E. Scharf
Journal: Blood (2005)
Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.
Authors: Alfonso Quintás-Cardama, Ayalew Tefferi, Deborah Thomas, Jorge Cortes, Farhad Ravandi, Stefan Faderl, Guillermo Garcia-Manero, Gautam Borthakur, Neda Bell, Catriona Byrne, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2007)
The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction.
Authors: Noor M Khaskhely, Daniela Buglio, Jessica Shafer, Catherine M. Bollard, Anas Younes
Journal: Blood (2009)
A Novel Direct STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition In a Wide Range of Hematopoietic Malignancies and Effectively Suppresses the Chemotherapy Resistant Quiescent Cells In Vivo
Authors: Fumihiko Hayakawa, Keiki Sugimoto, Shingo Kurahashi, Hironori Matsuyama, Yasuo Harada, Norikazu Hashimoto, Naoto Ohi, Takeshi Kodama, Takumi Sumida, Tomohiro Kinoshita, Tomoki Naoe
Journal: Blood (2010)
Different Patterns of Myocardial Iron Overload by T2* Cardiovascular MR As Markers of Risk for Cardiac Complication in Thalassemia Major,
Authors: Antonella Meloni, Pasquale Pepe, Petra Keilberg, Brunella Favilli, Vincenzo Positano, Marcello Capra, Vincenzo Caruso, Paolo Cianciulli, Aldo Filosa, Angelo Zuccarelli, Lucia De Franceschi, Massimo Lombardi, Alessia Pepe
Journal: Blood (2011)
Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network.
Authors: Wojciech Jurczak, Aleksander B. Skotnicki, Andrzej Deptala, Christine Windemuth-Kieselbach, Michael Lorsbach, Angelika Bischof Delaloye, Suh Cheolwon, Pier Luigi Zinzani, Roberto Cacchione, Werner Linkesch, Francesco d'Amore, Lorenz H. Truemper
Journal: Blood (2009)
Assisted partner services for HIV in Kenya: a cluster randomised controlled trial
Authors: Peter Cherutich, Matthew R Golden, Beatrice Wamuti, Barbra A Richardson, Kristjana H Ásbjörnsdóttir, Felix A Otieno, Ann Ng'ang'a, Peter Maingi Mutiti, Paul Macharia, Betsy Sambai, Matt Dunbar, David Bukusi, Carey Farquhar
Journal: The Lancet HIV (2016)
Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients
Authors: Gaelle Fossard, Emilie Blond, Stephane Giraudier, Stephane Morisset, Jeremy Ruby, Martine Escoffre-Barbe, Hélène Labussière-Wallet, Mael Heiblig, Madeleine Etienne, Jocelyne Drai, Mohamad Sobh, Mauricette Michallet, Isabelle Redonnet-vernhet, Jean-christophe Lega, Gabriel Etienne, Franck E. Nicolini
Journal: Blood (2014)
Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.
Authors: Rosana A Silveira, Angela A Fachel, Yuri B Moreira, Marcia T Delamain, Carmino Antonio De Souza, Fernando Ferreira Costa, Sergio Verjovski-Almeida, Katia B.B. Pagnano
Journal: Blood (2009)
Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome
Authors: Ana Elisa Lohmann, Pamela J. Goodwin, Rowan T. Chlebowski, Kathy Pan, Vuk Stambolic, Ryan J.O. Dowling
Journal: Journal of Clinical Oncology (2016)

Over the past 40 years, the prevalence of obesity has increased epidemically worldwide, which raises significant concerns regarding public health and the associated economic burden. Obesity is a major risk factor for several conditions including cardiovascular disease and type 2 diabetes, and recent evidence suggests that obesity negatively affects cancer risk and outcome. The relationship between obesity and cancer is complex and involves multiple factors both at the systemic and cellular level. Indeed, disruptions in insulin metabolism, adipokines, inflammation, and sex hormones all contribute to the adverse effects of obesity in cancer development and progression. The focus of this review will be the impact of these systemic obesity-related factors on cancer biology, incidence, and outcome. Potential therapeutic interventions and current clinical trials targeting obesity and its associated factors will also be discussed.
Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Authors: Brant A. Inman, Thomas A. Longo, Sundhar Ramalingam, Michael R. Harrison
Journal: Clinical Cancer Research (2016)

Atezolizumab (Tecentriq, MPDL3280A; Genentech/Roche) is an FcγR binding-deficient, fully humanized IgG1 mAb designed to interfere with the binding of PD-L1 ligand to its two receptors, PD-1 and B7.1. By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironment and, consequently, increases T-cell-mediated immunity against the tumor. Atezolizumab has been FDA approved as second-line therapy for advanced bladder cancer. This accelerated approval was based on phase II trial data in patients with metastatic bladder cancer that showed unexpected and durable tumor responses. In subjects whose tumors progressed on first-line platinum-based chemotherapy, the objective response rate was 15%, the complete response rate was 5%, and 1-year overall survival was 36%. In subjects that were chemotherapy naïve and cisplatin ineligible, the objective response rate was 24%, the complete response rate was 7%, and 1-year overall survival was 57%. Better responses were associated with higher PD-L1 expression on the tumor-infiltrating leukocytes. These data suggest that patients with advanced bladder cancer treated with atezolizumab have significantly better response rates and survival than historical controls treated with other second-line regimens. The toxicity profile of atezolizumab is also favorable. Trials are currently assessing whether atezolizumab is effective in earlier bladder cancer stages and in the first-line metastatic setting. Clin Cancer Res; 23(8); 1886-90. ©2016 AACR.
Novel Mouse Anti-Mouse β3 Integrin Monoclonal Antibodies: Development and Characterization of New Reagents for Research in Thrombosis and Thrombocytopenia.
Authors: Guangheng Zhu, Michelle Lee Webster, Adili Reheman, Pingguo Chen, Ebrahim Sayeh, Hong Yang, Ming Wang, John Freedman, Heyu Ni
Journal: Blood (2007)
Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)
Authors: Hiroaki Shimizu, Takayuki Saitoh, Shinichiro Okamoto, Yoshinobu Kanda, Heiwa Kanamori, Satoshi Takahashi, Kazuteru Ohashi, Kensuke Usuki, Chiaki Nakaseko, Makoto Onizuka, Toru Sakura, Moritaka Goto, Shingo Yano, Shin Fujisawa, Reiko Watanabe, Nobuyuki Aotsuka, Jun Taguchi, Naoto Tomita, Hisashi Wakita, Yasuhito Nannya
Journal: Blood (2015)
Intrinsic Survival Capacity of Cord Blood T cells is heterogeneous and Can Be Promoted by Repeated Low-Doses of Recombinant Interleukin-7,
Authors: Eva Deberranger, Laurent B Pascal, Jacques Trauet, Bachra Choufi, Stephanie Thiant, jean-Paul Dessaint, Ibrahim Yakoub-Agha, Myriam Labalette
Journal: Blood (2011)
Impact of HLA Class I Typing-Resolution and Mismatches on Survival and Graft-Versus-Host Disease in Patients after Hematopoietic Stem Cell Transplantations from Unrelated Donors.
Authors: Miroslaw Markiewicz, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Iwona Wylezol, Sebastian Giebel, Jerzy Holowiecki
Journal: Blood (2005)
A Small Molecule Inhibitor of D-Cyclin Transactivation Displays Preclinical Efficacy in Myeloma and Leukemia.
Authors: Xinliang Mao, Tabitha E Wood, Rose Hurren, Jiefei Tong, Xiaoming Wang, Paul A. Spagnuolo, Neil MacLean, Michael F. Moran, Alessandro Datti, Jeff Wrana, Robert A. Batey, Aaron D. Schimmer
Journal: Blood (2009)
The Mechanism of Type I Interferon-Mediated Polarization of Tumor-Associated Neutrophils in Mice and Human
Authors: Lisa Andzinski, Mozhgan Dehghan Harati, Edyta Zyla, Nadine Kasnitz, Stephanie Stahnke, Ching-Fang Wu, Marcus Gereke, Maren von Köckritz-Blickwede, Bastian Schilling, Sven Brandau, Lothar Kanz, Karl Welte, Siegfried Weiss, Julia Skokowa, Jadwiga Jablonska
Journal: Blood (2015)
Utilization of Leftover Autologous Peripheral Blood Stem Cells (PBSCs) in Patients with Multiple Myeloma (MM)
Authors: Natalie S Callander, Walter L. Longo, Mark B. Juckett, Vaishalee P. Kenkre, Peiman Hematti, Janelle McMannes, Rebecca K Evans, Linda A Eckstein, Blythe Gage
Journal: Blood (2014)
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.
Authors: Houchingue Eghbali, Pauline Brice, Geert-Yan Creemers, Marinus van Marwijk Kooij, Patrice Carde, Mars B. Van’t Veer, Elli Lugtenburg, Anne Sonet, Catherine Sebban, Michel Blanc, John M. Raemaekers, Laurent Voillat, Chantal Rieux, Ed M. Noordijk, Michel Henry-Amar
Journal: Blood (2005)
Human UCB CD133+ Cell Infusion In NOD-SCID Mice with Acute Hind Limb Ischemia Improves Reperfusion of An Ischemic Bed
Authors: Mathew Lesniewski, Jonathan Goldberg, Laura Fanning-Hammond, Marcie Finney, Margaret Forster, Cindy S. Chen, R. Patrick Weitzel, Patrick Leahy, Nicholas J Greco, Mary J. Laughlin
Journal: Blood (2010)
C-Cbl Regulates Interaction of Immature Hematopoietic Cells with the Bone Marrow Microenvironment by Rac GTPase-Mediated Cytoskeletal Signals.
Authors: Eisuke Uehara, Takahiro Suzuki, Hiroshi Okabe, Masuzu Ueda, Tadashi Nagai, Masashi Sanada, Seishi Ogawa, Keiya Ozawa
Journal: Blood (2009)